Advertisement

Topics

Clinical Trials About "A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients." RSS

09:35 EDT 20th October 2018 | BioPortfolio

We list hundreds of Clinical Trials about "A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients." on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients." on BioPortfolio

We have published hundreds of A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. news stories on BioPortfolio along with dozens of A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. Clinical Trials and PubMed Articles about A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. Companies in our database. You can also find out about relevant A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. Drugs and Medications on this site too.

Showing "Study Subcutaneous Mircera Treatment Anemia Dialysis Patients" Clinical Trials 1–25 of 29,000+

Extremely Relevant

A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients.

This single arm study will assess the efficacy, safety and tolerability of subcutaneous Mircera for correction of anemia and maintenance of hemoglobin levels in patients with chronic kidney disease who are not on dialysis and are not treated with ESA. Eligible patients will receive Mircera by monthly subcutaneous injections, dependent on body weight (with a recommended starting dose of 1.2 micrograms/kg). The anticipated time on study treatment is 3-12 months, and the target sa...


A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

This single arm study will assess the efficacy and safety of subcutaneous Mircera for correction and/or maintenance of hemoglobin levels in chronic kidney disease patients with renal anemia, who are not currently treated with ESA or on dialysis. Eligible patients will receive monthly subcutaneous injections of Mircera, at an initial recommended dose of 1.2 micrograms/kg. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

This single arm study will assess the efficacy and safety of monthly administration of subcutaneous Mircera when administered for the maintenance of hemoglobin levels in patients with chronic renal anemia, not on dialysis. Patients currently receiving treatment with subcutaneous epoetin or darbepoetin alfa will receive monthly subcutaneous injections of Mircera, with the starting dose (120 or 200 micrograms) calculated from the last weekly dose of ESA previously administered. T...


A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

This study will assess the efficacy and safety of subcutaneous (sc) Mircera give n as maintenance treatment for renal anemia in chronic kidney disease patients o n dialysis who were previously receiving sc epoetin. The anticipated time on stu dy treatment is 1-2 years and the target sample size is 100-500 individuals.

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease Not Treated With ESA or on Dialysis.

This single arm study will assess the efficacy and safety of subcutaneous Mircera for correction of anemia in patients with chronic kidney disease who are not treated with ESA and not on dialysis. Eligible patients will receive Mircera by monthly subcutaneous injections. The initial dose, based on body weight, will be 1.2 micrograms/kg. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.

This single arm study will assess the efficacy and safety of subcutaneous Mircera for the correction and maintenance of hemoglobin levels in predialysis patients with renal anemia who are not currently treated with ESA. Eligible patients will receive monthly subcutaneous injections at an initial recommended dose of 1.2 micrograms/kg. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not on Dialysis.

This single arm study will assess the efficacy and safety of subcutaneous Mircera when administered for the maintenance of hemoglobin levels in patients with chronic renal anemia, not on dialysis. Patients currently receiving maintenance treatment with subcutaneous darbepoetin alfa or epoetin beta will receive monthly injections of Mircera, with the starting dose (120, 200 or 360 micrograms s.c.) derived from the dose of darbepoetin alfa or epoetin beta they were receiving in t...

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

This study will assess the efficacy and safety of intravenous (iv) or subcutaneo us (sc) Mircera, administered with pre-filled syringes, as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previo usly receiving iv or sc epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia

This single arm study will assess the efficacy, safety and tolerability of once monthly administration of subcutaneous Mircera for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia.Patients will receive subcutaneous Mircera at a starting dose of 120 or 200 micrograms every 4 weeks, calculated from the last weekly dose of epoetin or darbepoetin alfa previously administered. Subsequent doses will be adjusted to maintain hemoglobin levels within t...

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease who are not on dialysis and who are receiving subcutaneous darbepoetin alfa maintenance therapy. Patients will be randomized either to remain on darbepoetin alfa therapy as per local label, or to switch to monthly subcutaneous Mircera, at a starting dose of 120, 200 or 360 micrograms, depending on the weekly dose of darbepoetin...

A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis

This single arm study will assess the efficacy, safety and tolerability of once monthly administration of subcutaneous Mircera for the maintenance of hemoglobin levels in patients with chronic renal anemia not on dialysis.Patients will receive sc Mircera at a starting dose of 100, 120, 150 or 200 micrograms every 4 weeks, calculated from the last weekly dose of ESA previously administered. Subsequent doses will be adjusted to maintain hemoglobin levels within the target range. ...

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

This 2 arm study will compare the efficacy of monthly Mircera and epoetin alfa in peritoneal dialysis patients who self-inject at home or receive in-centre injections. The safety of subcutaneous (sc) Mircera and injection site reactions and patient satisfaction will also be assessed. Eligible patients will be randomized either to receive monthly sc injections of Mircera (and will be switched from sc epoetin alfa) at a starting dose of 120-360 micrograms, or to remain on standar...

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

This study will determine the appropriate dose and frequency of administration of sc Mircera maintenance therapy in dialysis patients with chronic renal anemia who were previously receiving sc epoetin alfa or beta. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

This 2 arm study will compare the efficacy and safety of monthly administration of subcutaneous Mircera versus epoetin alfa for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia. Patients currently receiving maintenance treatment with epoetin alfa will be randomized to receive either monthly injections of Mircera with a starting dose (120, 200 or 360 micrograms) derived from the dose of epoetin alfa they were receiving in the week preceding stu...

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

This study will assess the efficacy and safety of subcutaneous Mircera in the tr eatment of renal anemia in patients with chronic kidney disease who are not on d ialysis and not receiving epoetin or any other erythropoietic substance. The ant icipated time on study treatment is 1-2 years and the target sample size is 100- 500 individuals.

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

This study will assess the efficacy and safety of intravenous (iv) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv darbepoetin alfa. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.

A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.

This single arm study will evaluate the hemoglobin (Hb) increasing effect, safety and tolerability of two-weekly intravenous administration of Mircera in dialysis patients with chronic renal anemia not currently treated with ESAs. Patients will receive intravenous Mircera 0.6 micrograms/kg every 2 weeks for 16 weeks with follow up 2 weeks after the last treatment visit. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa.

A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia

This open label, single arm study will assess the efficacy for long-term maintenance of haemoglobin levels and the safety and tolerability of methoxy polyethylene glycol-epoetin beta [Mircera] in dialysis patients with chronic renal anaemia. Patients on regular long-term haemodialysis or peritoneal dialysis will receive monthly subcutaneous or intravenous Mircera for 6 months. Target sample size is

A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.

This two arm study will compare the maintenance of hemoglobin levels, safety and tolerability of once every 4 weeks subcutaneous administration of Mircera versus epoetin beta in dialysis patients with chronic renal anemia. Patients will be randomized to receive either subcutaneous Mircera (starting dose 120, 200 or 360 micrograms) every 4 weeks or subcutaneous epoetin beta in accordance with the prescribed dosing information. In both groups, the starting dose will be the same a...

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

BCD-131 is pegylated darbepoetin beta. BCD-131-2 is International Multicenter Randomized Open-Label Comparative Study (Phase II) of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant

This 2 arm study will assess the efficacy, safety and tolerability of subcutaneous Mircera, versus no ESA therapy, in chronic kidney disease patients with anemia after kidney transplant, not currently treated with ESA. Patients will be randomized to receive a)subcutaneous Mircera at a recommended starting dose of 0.6 micrograms/kg every 2 weeks, switching to monthly treatment at week 16 or b)supportive treatment (eg. iron supplementation) for management of low hemoglobin concen...

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

This study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on dialysis. The anticipated time on study treatment is 3-12 months and the target sample size is

A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

This single arm study will assess the long term efficacy, safety and tolerability of intravenous (iv) or subcutaneous (sc) Mircera in chronic kidney disease patients with renal anemia. Eligible patients will be those who are currently receiving stable maintenance therapy with Mircera in Phase II or III clinical studies. They will continue to receive Mircera at the same weekly dose and by the same route of administration (sc or iv) every 2 or every 4 weeks, as in the qualifying ...


More From BioPortfolio on "A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients."

Advertisement
Quick Search
Advertisement
Advertisement